I just read the above article and noticed at the bottom it says SB Cardigan I and II trials used proprietary validated patient-reported outcome, HDSM-Ax score as the primary end point.
Does anyone know what this means?
The reason this comes to mind is because the mid-review cycle announcement mentioned the FDA just had to confirm efficacy and labelling.
I’m wondering if that confirmation of efficacy is somehow tied in with how the outcome was scored / assessed?
BOT - Anything but charting, page-5742
-
- There are more pages in this discussion • 4,535 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
-0.005(1.19%) |
Mkt cap ! $751.1M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 42.5¢ | 40.0¢ | $2.133M | 5.181M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 51664 | 40.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.5¢ | 341870 | 4 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |